Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Zippia finds jobs where you're a top candidate and applies on your behalf.
TransMedics's peak revenue was $441.5M in 2024. The peak quarterly revenue was $121.6M in 2024(q4).
TransMedics's revenue increased from $13.0m in 2018 to $441.5M currently. That's a 3,292.03% change in annual revenue.
| Fiscal year / year | TransMedics revenue |
|---|---|
| 2018 | $13.0M |
| 2019 | $23.6M |
| 2020 | $25.6M |
| 2021 | $30.3M |
| 2022 | $93.5M |
| 2023 | $241.6M |
| 2024 | $441.5M |
How accurately did TransMedics' revenue projections match actual performance?
TransMedics saw the greatest revenue growth in 2022, when revenue increased by 208.83%.
TransMedics had the lowest revenue growth in 2020, when revenue changed by 8.62%.
| Year | TransMedics growth |
|---|---|
| 2019 | 81%↑ |
| 2020 | 9%↑ |
| 2021 | 18%↑ |
| 2022 | 209%↑ |
| 2023 | 159%↑ |
| 2024 | 83%↑ |
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2018 | - | - | - | $3.5M |
| 2019 | $4.7M | $5.7M | $7.2M | $6.1M |
| 2020 | $7.5M | $3.4M | $7.1M | $7.6M |
| 2021 | $7.1M | $8.2M | $5.4M | $9.7M |
| 2022 | $15.9M | $20.5M | $25.7M | $31.4M |
| 2023 | $41.6M | $52.5M | $66.4M | $81.2M |
| 2024 | $96.9M | $114.3M | $108.8M | $121.6M |
Do you work at TransMedics?
Is TransMedics transparent about its revenue structure?
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 110 |
| Date Founded | 1998 |
| Headquarters | Andover, Massachusetts |
| Revenue | $441.5M |
| Net Income | -$36,231,000 |
| Gross Proft | $262.1M (2024) |
| Tax Rate | 0.0% |
| Total Assets | $277,147,000 |
| Ticker | TMDX |
TransMedics received early financing of $8.0M on 2000-09-21.
| Series | Round size | Date |
|---|---|---|
| Series A | $8M | 09/2000 |
| Series B | $27.6M | 01/2004 |
| Series C | $29.8M | 03/2006 |
| Series D | $25.5M | 04/2007 |
| Debt Financing | $2.5M | 07/2009 |
| Debt Financing | $3.6M | 11/2009 |
| Series E | $36M | 03/2010 |
| Series Unknown | $6M | 08/2011 |
| Series Unknown | $36M | 11/2012 |
| Series Unknown | $20M | 06/2015 |
| Series Unknown | $500K | 09/2015 |
| Series F | $51.2M | 05/2016 |
| Private Equity | $12.5M | 07/2016 |
| Post Ipo Debt | $2.2M | 04/2020 |
| Investors | Security type |
|---|---|
| Sofinov Societe Financiere D'Innovation | Series A |
| MEDEQUITY CAPITAL LLC | Series A |
| Alta Partners | Series A |
| WASHINGTON MUTUAL BANK | Series A |
| Novel Bioventures LLC | Series B |
| Sherbrooke Capital | Series B |
| CDP Capital Technology Ventures | Series B |
| CB Health Ventures LLC | Series B |
| 3i PLC | Series B |
| Alta Partners | Series B |
| POSCO BioVentures Inc | Series B |
| Flagship Pioneering Inc | Series B |
| Vantage Point Capital Partners | Series C |
| Sherbrooke Capital | Series C |
| CB Health Ventures LLC | Series C |
| Sagamore Bioventures | Series C |
| 3i PLC | Series C |
| Alta Partners | Series C |
| POSCO BioVentures Inc | Series C |
| Flagship Pioneering Inc | Series C |
| Vantage Point Capital Partners | Series D |
| Sherbrooke Capital | Series D |
| CB Health Ventures LLC | Series D |
| Sagamore Bioventures | Series D |
| Tudor Investments | Series D |
| 3i PLC | Series D |
| Alta Partners | Series D |
| POSCO BioVentures Inc | Series D |
| Flagship Pioneering Inc | Series D |
| Vantage Point Capital Partners | Series E |
| Foundation Capital LLC | Series E |
| Sherbrooke Capital | Series E |
| Excel Venture Management | Series E |
| CB Health Ventures LLC | Series E |
| Sagamore Bioventures | Series E |
| 3i PLC | Series E |
| Tudor Investments | Series E |
| Alta Partners | Series E |
| Kleiner Perkins | Series E |
| POSCO BioVentures Inc | Series E |
| Flagship Pioneering Inc | Series E |
| Abrams Capital | Series Unknown |
| Kleiner Perkins | Series Unknown |
| Flagship Pioneering Inc | Series Unknown |
| HERCULES CAPITAL INC | Series Unknown |
| Lung Biotechnology PBC | Series F |
| Abrams Capital | Series F |
| BioStar Capital | Series F |
| Inbio Ventures | Series F |
| Millhouse Capital | Series F |
| Kleiner Perkins | Series F |
| Flagship Pioneering Inc | Series F |
| Fayerweather Fund | Series F |
| Lung Biotechnology PBC | Private Equity |
| Abrams Capital | Private Equity |
| Pharmstandard | Private Equity |
| BioStar Capital | Private Equity |
| Inbio Ventures | Private Equity |
| Kleiner Perkins | Private Equity |
| Flagship Pioneering Inc | Private Equity |
| Fayerweather Fund | Private Equity |
TransMedics's top competitor, Emergent BioSolutions, earned an annual revenue of $1.6B.
TransMedics's smallest competitor is Abiomed with revenue of $1.0B last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| CoolSculpting | $73,648 | $342.1M | 686 | - |
| Caliper Life Sciences | $81,030 | $109.8M | 200 | - |
| Emergent BioSolutions | $77,521 | $1.6B | 1,834 | 8 |
| Epic Sciences | $45,673 | $1.0M | 10 | 6 |
| Aastrom Biosciences | $51,812 | - | - | - |
| Cubist Pharmaceuticals | $91,725 | $926.4M | 873 | - |
| Intercept Pharmaceuticals | $93,850 | $285.7M | 437 | - |
| UFP Technologies | $40,203 | $504.4M | 1,828 | 35 |
| TransEnterix | $74,555 | $3.2M | 128 | - |
| Infraredx | $48,434 | $4.5M | 50 | - |
Zippia gives an in-depth look into the details of TransMedics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about TransMedics. The employee data is based on information from people who have self-reported their past or current employments at TransMedics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by TransMedics. The data presented on this page does not represent the view of TransMedics and its employees or that of Zippia.
TransMedics may also be known as or be related to TransMedics, TransMedics Inc, TransMedics, Inc., Transmedics and Transmedics, Inc.